$8.61
-0.14[-1.60%]
At close: Apr 25
$8.61
0[0.00%]
After Hours: 5:07PM EDT
Arcutis Biotherapeutics
(NASDAQ:ARQT)Latest News for Arcutis Biotherapeutics Stock (NASDAQ:ARQT)
Arcutis Biotherapeutics Stock (NASDAQ: ARQT)
Categories: All
Friday, April 12, 2024
Wednesday, April 10, 2024
Monday, March 11, 2024
- EQT, Genie Energy And Other Big Stocks Moving Lower On MondayAvi Kapoor - Mar 11, 2024, 10:37AM
- Sunday, Arcutis Biotherapeutics' New Data From INTEGUMENT-PED Phase 3 Study Of Roflumilast Cream In Children 2 To 5 Years With Mild To Moderate Atopic Dermatitis Showed Significant Improvements Across Multiple Efficacy Endpoints And All TimepointsBenzinga Newsdesk - Mar 11, 2024, 5:11AM
Thursday, February 29, 2024
Wednesday, February 28, 2024
- Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan; The Arcutis To Receive A $25M Upfront Payment, And Is Eligible To Receive Potential Development And Commercial Milestone Payments Totaling $40MBenzinga Newsdesk - Feb 28, 2024, 4:03PM
- Goldman Sachs Maintains Neutral on Arcutis Biotherapeutics, Raises Price Target to $11Benzinga Newsdesk - Feb 28, 2024, 11:21AM
- Mizuho Reiterates Buy on Arcutis Biotherapeutics, Raises Price Target to $17Benzinga Newsdesk - Feb 28, 2024, 8:54AM
- Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their ViewsBenzinga Insights - Feb 28, 2024, 8:00AM
- Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $16Benzinga Newsdesk - Feb 28, 2024, 7:39AM
Tuesday, February 27, 2024
- Arcutis Biotherapeutics Q4 2023 GAAP EPS $(0.72) Beats $(0.76) Estimate, Sales $13.53M Beat $11.34M EstimateBenzinga Newsdesk - Feb 27, 2024, 5:55AM
- Arcutis Biotherapeutics Expects Continued Reductions In R&D Expenses In 2024 As It Focuses Investments In Ongoing Commercial Launches For Zoryve (Roflumilast) Topical Foam For Seborrheic DermatitisBenzinga Newsdesk - Feb 27, 2024, 5:54AM
- Arcutis Biotherapeutics Q4 GAAP EPS $(0.72) Beats $(0.78) Estimate, Sales $13.53M Beat $11.34M EstimateBenzinga Newsdesk - Feb 27, 2024, 5:52AM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 19, 2024
Friday, February 09, 2024
Thursday, February 01, 2024
- Arcutis Biotherapeutics shares are trading higher after Steven Cohen reported a 5.2% passive stake in the company in a 13G filing.Benzinga Newsdesk - Feb 1, 2024, 2:09PM
- MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAvi Kapoor - Feb 1, 2024, 5:10AM
Wednesday, January 31, 2024
Monday, January 29, 2024
Tuesday, January 23, 2024
Monday, January 22, 2024
- Arcutis Biotherapeutics shares are trading higher after the company announced the launch of ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis.Benzinga Newsdesk - Jan 22, 2024, 10:36AM
- Arcutis Biotherapeutics, Inc. Announces ZORYVE Topical Foam, 0.3%, For The Treatment Of Seborrheic Dermatitis Launches In The United StatesBenzinga Newsdesk - Jan 22, 2024, 8:17AM
Friday, January 19, 2024
Tuesday, January 16, 2024
Friday, January 12, 2024
Wednesday, January 03, 2024
- Arcutis Biotherapeutics shares are trading higher after Mizuho upgraded the stock from Neutral to Buy and raised its price target from $4 to $8.Benzinga Newsdesk - Jan 3, 2024, 1:04PM
- Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 AnalystsBenzinga Insights - Jan 3, 2024, 7:00AM
- Mizuho Upgrades Arcutis Biotherapeutics to Buy, Raises Price Target to $8Benzinga Newsdesk - Jan 3, 2024, 4:39AM
Tuesday, January 02, 2024
Thursday, December 28, 2023
Tuesday, December 19, 2023
Monday, December 18, 2023
- Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Dec 18, 2023, 1:05PM
- Arcutis Biotherapeutics shares are trading higher after the FDA approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older.Benzinga Newsdesk - Dec 18, 2023, 10:12AM
- Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Dec 18, 2023, 8:10AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Dec 18, 2023, 8:08AM
- FDA Approves Arcutis Biotherapeutics' Lead Drug For Scaly Skin DisorderVandana Singh - Dec 18, 2023, 7:03AM
Saturday, December 16, 2023
- Arcutis Biotherapeutics Says STRATUM Study Met Its Primary Endpoint, With Nearly 80% Of ZORYVE Foam Treated Individuals Reaching Investigator Global Assessment; Also Demonstrated Improvement On All Secondary Endpoints, Including Itch, Scaling And ErythemaBenzinga Newsdesk - Dec 16, 2023, 6:57PM
- FDA Approves Arcutis' ZORYVE Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And OlderHappy Mohamed - Dec 16, 2023, 6:41PM
Friday, December 15, 2023
Wednesday, November 29, 2023
Monday, November 13, 2023
Wednesday, November 08, 2023
Monday, November 06, 2023
- What 8 Analyst Ratings Have To Say About Arcutis BiotherapeuticsBenzinga Insights - Nov 6, 2023, 8:00AM
- DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For MondayLisa Levin - Nov 6, 2023, 7:31AM
- Needham Maintains Buy on Arcutis Biotherapeutics, Lowers Price Target to $8Benzinga Newsdesk - Nov 6, 2023, 6:59AM
- HC Wainwright & Co. Maintains Buy on Arcutis Biotherapeutics, Lowers Price Target to $8Benzinga Newsdesk - Nov 6, 2023, 6:50AM